AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16706755
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (Vit C) cream applied twice daily for 3 months
Trial: 11397885
Drug: 10% lipid
RxNorm normalized name: Liposyn II 10% Lipid Emulsion for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lipid emulsion infusion + heparin (n = 15)
Trial: 11397885
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (control study; n = 15)
Trial: 11397885
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin treatment after 3 months (n = 30)
Trial: 7944453
Drug: Intraaortic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraaortic chemotherapy (IA)
Trial: 31642037
Drug: Brexanolone injection
RxNorm normalized name: brexanolone Injection
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brexanolone injection
Trial: 24490025
Drug: Sertindole (16-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole (16-24 mg)
Trial: 19542525
Drug: Olanzapine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-20 mg)
Trial: 20728522
Drug: gp120/NefTat candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120/NefTat candidate HIV-1 vaccine with AS01(B)
Trial: 20728522
Drug: gp120/NefTat candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120/NefTat candidate HIV-1 vaccine with AS02(A)
Trial: 20728522
Drug: gp120/NefTat candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120/NefTat candidate HIV-1 vaccine with AS02(V)
Trial: 20728522
Drug: gp120/NefTat candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120/NefTat candidate HIV-1 vaccine
Trial: 18991469
Drug: LNX‐QR 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNX‐QR 8 mg tablet
Trial: 18991469
Drug: LNX‐ST 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNX‐ST 8 mg tablet
Trial: 11798692
Drug: Losec (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losec (40 mg)
Trial: 11798692
Drug: Aoke‐Changzhou No.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aoke‐Changzhou No.4 Pharm (40 mg)
Trial: 11798692
Drug: Omeprazole‐Sanye Pharm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole‐Sanye Pharm (40 mg)
Trial: 8683228
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and fluorouracil (M‐‐>F)
Trial: 6348763
Drug: Steroids or
RxNorm normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids or chlorambucil given in alternate months for a cumulative period of six months
Trial: 6348763
Drug: Steroids or
RxNorm normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids or chlorambucil
Trial: 28554173
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day
Trial: 25367235
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg administered 2 minutes before aortic declamping)
Trial: 25367235
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg intravenously administered 15 minutes before release of aortic cross clamp)
Trial: 22965962
Drug: (ziv‐)aflibercept 6
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (ziv‐)aflibercept 6 mg/kg IV + docetaxel 75 mg/m²
Trial: 22965962
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + docetaxel 75 mg/m²
Trial: 15924594
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg on-demand
Trial: 12590989
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of in-person with physician letter
Trial: 10496434
Drug: d,l-sotalol 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-sotalol 80 mg twice daily
Trial: 10496434
Drug: d,l-sotalol 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-sotalol 120 mg twice daily
Trial: 10496434
Drug: d,l-sotalol 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-sotalol 160 mg twice daily
Trial: 1745318
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 9 g/24 hours
Trial: 1745318
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 6 g/24 hours
Trial: 31277184
Drug: 25G needle
RxNorm normalized name: NEEDLE 25G 1IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25G needle through the lateral crypt (group L, n=30)
Trial: 22119244
Drug: K-134 50
RxNorm normalized name: K-134
DrugBank: K-134 (DB12685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-134 50 mg
Trial: 22119244
Drug: K-134 100
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-134 100 mg
Trial: 17503880
Drug: Next generation
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next generation drug-eluting stents (including sirolimus analogs, biodegradable and bioabsorbable materials)
Trial: 17503880
Drug: Reservoir stents
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reservoir stents with different drug release profiles
Trial: 15489844
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus tianeptine 37.5 mg/day
Trial: 16123227
Drug: Clonidine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (15 mg/week for 8 weeks)
Trial: 27937084
Drug: Rebamipide (REB)
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide (REB) ophthalmic suspension
Trial: 27937084
Drug: Diquafosol (DQS)
DrugBank: Diquafosol (DB15919)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Diquafosol (DQS) ophthalmic solution
Trial: 26785125
Drug: Self-reported frequency
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported frequency of doses taken
Trial: 26785125
Drug: Self-reported percentage
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported percentage of doses taken
Trial: 26785125
Drug: Unannounced pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unannounced pill counts (UPC)
Trial: 26785125
Drug: Plasma tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plasma tenofovir levels (SSDD; ≥40 ng/ml)
Trial: 24504688
Drug: Metoclopramide (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (7 mg) plus dimeticone (40 mg) and pepsin (50 mg)
Trial: 24504688
Drug: Conventional metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metoclopramide capsule (7 mg)
Trial: 21750253
Drug: QUI (quinapril)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUI (quinapril) 40 mg/d
Trial: 21750253
Drug: QUI +
RxNorm normalized name: Quinidine
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QUI + ALA (quinapril 40 mg/d + α-lipoic acid 600 mg/d)
Trial: 17445589
Drug: Alendronate 35
RxNorm normalized name: ALENDRONATE 35MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 35 mg/wk for 6 months (Group A)
Trial: 9803777
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet with hypercaloric supplement (Suplena)
Trial: 9803777
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same low-protein diet, 0.6 g protein/kg/day)
Trial: 28182279
Drug: AMIO +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMIO + RAN (1 g oral dose)
Trial: 28182279
Drug: AMIO (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMIO (5 mg/kg loading dose followed by 50 mg/h)
Trial: 21714757
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg) administered daily for four weeks
Trial: 21714757
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for four weeks
Trial: 19781325
Drug: Hyperoxygenated solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperoxygenated solution (HO group, n = 109)
Trial: 19781325
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (NO group, n = 115)
Trial: 3541602
Drug: Prazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (1 mg two times daily to maximum of 20 mg per day)
Trial: 3541602
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg three times daily to a maximum of 450 mg per day)
Trial: 31593299
Drug: 5 mL lidocaine
RxNorm normalized name: lidocaine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL lidocaine 2% diluted in 15 mL normal saline
Trial: 31593299
Drug: 20 mL normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL normal saline alone
Trial: 19293592
Drug: Dual blockade
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual blockade with ACE inhibitor and angiotensin II receptor blocker
Trial: 16437672
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g twice a day)
Trial: 10496437
Drug: candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: candesartan cilexetil 8 mg once daily
Trial: 10496437
Drug: candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: candesartan cilexetil 16 mg once daily
Trial: 30588956
Drug: Advagraf (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advagraf (once-daily tacrolimus)
Trial: 30588956
Drug: Prograf (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf (twice-daily tacrolimus)
Trial: 26767411
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (SC) 50 mg capsules, maximum 150 mg, given eight hourly during labour
Trial: 26767411
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given eight hourly during labour
Trial: 24694207
Drug: Self-Management education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Management education for epilepsy (SMILE (UK) course with treatment as usual)
Trial: 22316315
Drug: Vaginal gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel containing isoflavones, Lactobacillus sporogenes, Calendula officinalis extract and lactic acid (Estromineral Gel, Rottapharm‐Madaus) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Trial: 22316315
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical treatment (NT) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Trial: 20807792
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm l‐NAME
Trial: 20807792
Drug: Combined 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 20 mm capsazepine + 10 mm l‐NAME
Trial: 20807792
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control (90% propylene glycol + 10% lactated Ringer solution)
Trial: 16097707
Drug: antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibacterial therapy
Trial: 16097707
Drug: antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibacterial therapy + alpha-adrenoblockers
Trial: 16097707
Drug: antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibacterial therapy + transrectal laser and magnetic physiotherapy
Trial: 16097707
Drug: antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibacterial therapy + alpha-adrenoblockers + transrectal laser and magnetic physiotherapy
Trial: 11849155
Drug: Allogeneic human
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic human tumour cell vaccine with Mycobacterium vaccae (SRL‐172)
Trial: 7581527
Drug: BCG full
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG full dose
Trial: 2184287
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (5 mg/kg over 20 minutes)
Trial: 2184287
Drug: Oral quinidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinidine (400 mg immediately and 400 mg in 4 hours)
Trial: 6115246
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) (200 mg/day)
Trial: 6115246
Drug: Mebendazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (2 g/day)
Trial: 6115246
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg per week)
Trial: 27191247
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of red grape seed extract (RGSE) for eight weeks
Trial: 18030411
Drug: Postoperative multidisciplinary,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative multidisciplinary, multifactorial fall-prevention program including staff education, systematic assessment and treatment of fall risk factors, vitamin D and calcium supplementation
Trial: 16816303
Drug: Risperidone or
RxNorm normalized name: risperidone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone or Haloperidol (flexible dose, median treatment length 206 days)
Trial: 12816293
Drug: Herbal-based mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal-based mouthrinse with oral irrigator
Trial: 12816293
Drug: Conventional mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional mouthwash with oral irrigator
Trial: 30048547
Drug: Oligofructose (OF)
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (OF) 7g twice daily
Trial: 30048547
Drug: Maltodextrin (MD)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (MD) 7g twice daily
Trial: 27235528
Drug: Mobi-C implant
RxNorm normalized name: Synovex C Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobi-C implant
Trial: 15992789
Drug: PTCA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTCA therapy
Trial: 15992789
Drug: Non-therapy patients
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-therapy patients
Trial: 10231223
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy (N‐acetylcysteine, selenium, vitamins C and E) for 7 days
Trial: 6363154
Drug: Cotrimazine (sulfadiazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimazine (sulfadiazine 900 mg + trimethoprim 300 mg)
Trial: 6363154
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g daily
Trial: 27266229
Drug: Plai cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plai cream (n = 70 patients)
Trial: 22874106
Drug: Ferumoxytol (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (two 510 mg i.v. injections within 5 ± 3 days)
Trial: 12598441
Drug: NSAID ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID ophthalmic solution (bromfenac sodium hydrate) co-administered twice daily for 2 weeks
Trial: 12598441
Drug: Latanoprost ophthalmic
RxNorm normalized name: latanoprost ophthalmic
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost ophthalmic solution administered once daily
Trial: 12598441
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of bromfenac sodium hydrate ophthalmic solution
Trial: 12598441
Drug: Re-administration of
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-administration of bromfenac sodium ophthalmic solution
Trial: 6347277
Drug: Tamoxifen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen and No further therapy (both)
Trial: 30475959
Drug: Higher-protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein group (>0.80 g · kg‐1 · d‐1)
Trial: 30475959
Drug: Lower-protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-protein group (≤0.80 g · kg‐1 · d‐1)
Trial: 26654738
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution (RLS)
Trial: 21935814
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg, 2 capsules of 5 mg each)
Trial: 23222289
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules)
Trial: 17186724
Drug: Qianggan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggan Capsule combined with Lamivudine
Trial: 17186724
Drug: Qianggan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggan Capsule alone
Trial: 10875616
Drug: gp120 vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120 vaccines
Trial: 8864325
Drug: Reboxetine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 0.5 mg, 1 mg, or 4 mg
Trial: 8864325
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg with alcohol (0.6 mg kg‐1)
Trial: 8864325
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with alcohol (0.6 mg kg‐1)
Trial: 1497132
Drug: bupivacaine+buprenorphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine+buprenorphine (0.3 mg)
Trial: 6407433
Drug: Calcium inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium inhibitors
Trial: 30236904
Drug: Home-based biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based biofeedback therapy (20 min self-training sessions twice per day using a self-inserted probe for visual feedback)
Trial: 30236904
Drug: Office-based biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based biofeedback therapy (therapist-guided pelvic floor training for six sessions over 3 months)
Trial: 24691901
Drug: Nitazoxanide 675
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 675 mg
Trial: 24691901
Drug: Nitazoxanide 2700
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 2700 mg
Trial: 25239216
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) supplementation (maltodextrin solution)
Trial: 7758234
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 micrograms subcutaneous injections, 3 injections over one day)
Trial: 7758234
Drug: Placebo (octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (octreotide vehicle, 3 injections over one day)
Trial: 6163281
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate 600 mg daily
Trial: 30782701
Drug: Usual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual and Customary Treatment (UCT)
Trial: 24049109
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg dmLT
Trial: 24049109
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg dmLT
Trial: 24049109
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg dmLT
Trial: 24049109
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg dmLT